Brian Ritchie
LifeSci Advisors
Replay available
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call
Relmada Therapeutics, Inc. (NASDAQ: RLMD) Q4 2025 earnings conference call, held 2026-03-19. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Sergio Traversa
Chief Executive Officer
Dr. Raj Pruthi
Chief Medical Officer, Oncology
Maga Chenauda
Chief Financial Officer
Wei Yier
Analyst, Mizuho Securities
Farzin Haque
Analyst, Jefferies
Kelsey Goodwin
Analyst, Piper Sandler
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Relmada Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.236 Good afternoon and welcome to the Relmada Therapeutics fourth quarter and full year 2025 00:00:05.236 -- 00:00:10.300 earnings conference call. At this time, all participants are in a listen-only 00:00:10.300 -- 00:00:14.864 mode. After the prepared remarks, we will conduct a question and answer session. 00:00:14.864 -- 00:00:19.609 To ask a question, please press star 1. As a reminder, this conference call is being 00:00:19.609 -- 00:00:24.153 recorded and will be available for replay on the Relmada website. 00:00:24.153 -- 00:00:28.577 I would now like to turn the call over to Brian Ritchie from LifeSci Advisors. 00:00:28.577 -- 00:00:31.498 Please go ahead, Mr. Ritchie. 00:00:31.756 -- 00:00:34.940 Good day, everyone, and thank you for joining us today. 00:00:34.940 -- 00:00:40.308 This afternoon, Ramada issued a press release providing a business update and outlining 00:00:40.308 -- 00:00:46.574 its financial results for the three months and year ended December 31st, 2025. 00:00:46.676 -- 00:00:51.443 Please note that certain information discussed on the call today is covered under the 00:00:51.443 -- 00:00:56.290 safe harbor provision of the Private Securities Litigation Reform Act. 00:00:56.290 -- 00:01:01.469 We caution listeners that during this call, Romada's management team will be making 00:01:01.469 -- 00:01:03.471 forward-looking statements. 00:01:03.471 -- 00:01:08.656 Actual results could differ materially from those stated or implied by these 00:01:08.656 -- 00:01:13.821 forward-looking statements due to risks and uncertainties associated with the company's 00:01:13.821 -- 00:01:18.766 business. These forward-looking statements are qualified by the cautionary statements 00:01:18.766 -- 00:01:24.472 contained in Roma...